Table 1.

Key Model Inputs

Variable	Base	Min	Max	Distribution	Source
PFS survival model
Log-logistic-Tislelizumab+ chemotherapy	λ=8.07, γ=1.78
Lognormal-Chemotherapy alone	Meanlog=4.53, sdlog=3.20
OS survival model
Log-logistic-Tislelizumab+ chemotherapy	λ=17.59, γ=1.64
Log-logistic-Chemotherapy alone	λ=11.75, γ=1.67
Cost input, $/per cycle
Tislelizumab (200mg)	409.92	327.93	409.92	Gamma	Local charge
Paclitaxel(30mg)	23.96	19.17	23.96	Gamma	Local charge
Cisplatin(30mg)	2.84	2.28	2.84	Gamma	Local charge
Routine follow-up cost per cycle	27.42	21.93	32.90	Gamma	Local charge
Administration per cycle	435.21	348.17	522.26	Gamma	Local charge
Laboratory tests and radiological examinations/per cycle-pfs	84.76	67.81	101.71	Gamma	Local charge
Laboratory tests and radiological examinations/per cycle-pd	10.06	8.05	12.07
Hospitalization and daily care	89.27	71.42	107.13	Gamma	Local charge
Anemia’s treatment-	371.98	297.58	446.37	Gamma	Local charge
Decreased neutrophil count ‘s treatment	462.19	369.75	554.62	Gamma	Local charge
Decreased white blood cell count ‘s treatment	462.19	369.75	554.62	Gamma	Local charge
Body surface area (meters2)	1.72	1.38	2.06	Normal	[24]
Discount rate	0.05	0.00	0.08	Fixed	[24]
Utility input
Utility of PFS	0.74	0.59	0.89	Beta	[25]
Utility of PD	0.58	0.46	0.70	Beta	[25]
Disutility due to AEs
Anaemia	0.07	0.06	0.08	Beta	[26]
Decreased neutrophil count	0.20	0.16	0.24	Beta	[26]
Decreased white blood cell count	0.20	0.16	0.24	Beta	[26]
Risk for main AEs in tislelizumab plus chemotherapy group
Anaemia	0.15	0.12	0.18	Beta	[14]
Decreased neutrophil count	0.31	0.248	0.372	Beta	[14]
Decreased white blood cell count	0.11	0.088	0.132	Beta	[14]
Risk for main AEs in chemotherapy alone group
Anaemia	0.13	0.104	0.156	Beta	[14]
Decreased neutrophil count	0.33	0.264	0.396	Beta	[14]
Decreased white blood cell count	0.16	0.128	0.192	Beta	[14]

Abbreviations: OS, overall survival; PD, progressed disease; PFS, progression-free survival; AE, adverse event.